- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
Patent holdings for IPC class A61K 31/505
Total number of patents in this class: 5237
10-year publication summary
|
310
|
280
|
311
|
297
|
313
|
264
|
263
|
271
|
278
|
56
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 10420 |
84 |
| Merck Sharp & Dohme LLC | 3719 |
80 |
| Bristol-myers Squibb Company | 4821 |
74 |
| Janssen Sciences Ireland Unlimited Company | 384 |
58 |
| Boehringer Ingelheim International GmbH | 4567 |
57 |
| Rigel Pharmaceuticals, Inc. | 512 |
53 |
| Janssen Pharmaceutica N.V. | 3262 |
44 |
| Acetylon Pharmaceuticals, Inc. | 67 |
44 |
| Merck Sharp & Dohme Corp. | 2185 |
41 |
| Amarin Pharmaceuticals Ireland Limited | 273 |
41 |
| AstraZeneca AB | 2832 |
38 |
| Abbvie Inc. | 1848 |
38 |
| Takeda Pharmaceutical Company Limited | 2726 |
36 |
| ViiV Healthcare Company | 164 |
32 |
| The Regents of the University of California | 20502 |
31 |
| Dana-Farber Cancer Institute, Inc. | 2629 |
31 |
| F. Hoffmann-La Roche AG | 7847 |
29 |
| Signal Pharmaceuticals, LLC | 177 |
25 |
| Merck Patent GmbH | 5723 |
23 |
| Genentech, Inc. | 4065 |
21 |
| Other owners | 4357 |